4DMedical Ltd (ASX:4DX) saw its stock price soar 5.79% during intraday trading on Monday, marking a significant upward movement for the medical imaging technology company.

The sharp price increase appears to be driven by two key developments. First, the company has scheduled a special call to present on the clinical use of its CT:VQ non-contrast post-processing technology, drawing fresh attention to how this lung imaging software might fit into everyday healthcare workflows. This comes as the company's CT:VQ technology is being described as the first non-invasive, contrast-free imaging technology for lung scanning.

Second, 4DMedical announced it has signed an agreement to acquire Contextflow to establish a European commercial and clinical platform. The acquisition terms include A$18.56 million in cash, 56,235 shares, and up to 2.59 million options, representing a strategic move to expand the company's presence in the European market through this acquisition.